false 0000876378 0000876378 2023-06-05 2023-06-05
 


 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
 

 
FORM 8-K
 

 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 
June 5, 2023
Date of Report (date of earliest event reported)
 

 
Asensus Surgical, Inc.
(Exact name of Registrant as specified in its charter)
 

 
Delaware
(State or other jurisdiction of incorporation or organization)
 
0-19437
(Commission
File Number)
 
11-2962080
(I.R.S. Employer
Identification Number)
 
1 TW Alexander Drive, Suite 160
Durham, NC 27703
(Address of principal executive offices)
919-765-8400
(Registrants telephone number, including area code)
 
Not Applicable
(Former name or former address, if changed since last report)
 

 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
 
Trading symbol
 
Name of each exchange on which registered
Common Stock
$0.001 par value per share
 
ASXC
 
NYSE American
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 


 
 

 
Item 7.01 Regulation FD Disclosure
 
On June 5, 2023, Asensus Surgical, Inc. (the “Company”) updated its corporate presentation. The updated presentation is furnished as Exhibit 99.1 to this Form 8‑K.
 
The information in this Item 7.01 and the Exhibit 99.1 attached hereto shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
 
 
Item 9.01         Financial Statements and Exhibits.
 
(d) Exhibit    
       
  Exhibit. Description  
       
  99.1 Corporate Presentation of Asensus Surgical, Inc. June 5, 2023  
       
  104 Cover Page Interactive Data File (formatted in inline XBRL)  
         
 

 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
  ASENSUS SURGICAL, INC.
   
Date: June 5, 2023 /s/ Shameze Rampertab
  Shameze Rampertab
  Executive Vice President and Chief Financial Officer
 
 
TransEnterix (AMEX:TRXC)
과거 데이터 주식 차트
부터 11월(11) 2024 으로 12월(12) 2024 TransEnterix 차트를 더 보려면 여기를 클릭.
TransEnterix (AMEX:TRXC)
과거 데이터 주식 차트
부터 12월(12) 2023 으로 12월(12) 2024 TransEnterix 차트를 더 보려면 여기를 클릭.